Umbilical Cord Blood Stem Cell Treatment for Knee Osteoarthritis in Korea
Advanced Regenerative Therapy for Knee Cartilage Repair
Umbilical cord blood stem cell therapy is an advanced regenerative treatment designed to repair damaged cartilage in patients with knee osteoarthritis. At Gangnam JS Hospital in Korea, this therapy uses allogenic mesenchymal stem cells (MSCs) derived from donated umbilical cord blood to stimulate cartilage regeneration and improve joint function.
Unlike temporary pain-control injections, this approach targets the underlying cartilage defect, aiming to restore structural integrity inside the knee joint.
What Is Umbilical Cord Blood Stem Cell Therapy?
This treatment uses laboratory-expanded umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs). These cells are:
- Allogenic (donor-derived, not taken from the patient)
- Low immunogenic (minimal rejection risk)
- Expanded under controlled laboratory conditions
- Implanted directly into cartilage defect areas
In Korea, a well-known product used for this purpose is Cartistem®, which combines MSCs with hyaluronic acid for implantation into damaged cartilage.
Who Is a Candidate?
This procedure may be appropriate for:
- Moderate to severe knee osteoarthritis
- Focal cartilage defects
- Persistent knee pain despite conservative treatment
- Patients wishing to delay or avoid total knee replacement
- Active adults seeking joint preservation
Final eligibility depends on cartilage condition, joint alignment, age, and overall knee stability.
Procedure Overview
- Comprehensive Evaluation
MRI and imaging studies assess cartilage damage and joint alignment. - Surgical Implantation
The MSC product is implanted directly into the cartilage defect site during a minimally invasive procedure. - Biological Regeneration Phase
The implanted cells support regeneration of hyaline-like cartilage tissue over time. - Structured Rehabilitation
Progressive weight-bearing and physiotherapy support joint recovery.
Expected Benefits
- Reduction in knee pain
- Improved mobility and function
- Cartilage regeneration at defect sites
- Potential delay of total knee replacement surgery
- Joint preservation strategy for active patients
Outcomes vary depending on severity of osteoarthritis and rehabilitation adherence.
Recovery Timeline
- Hospital Stay: Short-term admission (varies by case)
- Initial Recovery: Limited weight-bearing for several weeks
- Rehabilitation: 3–6 months structured rehab
- Full Functional Improvement: Gradual improvement over 6–12 months
Cartilage regeneration is a biological process and requires time.
Why Korea for Umbilical Cord Blood Stem Cell Therapy?
Korea is one of the first countries to approve and commercialize umbilical cord blood–derived MSC products for knee cartilage regeneration. Treatment protocols are regulated and performed under strict clinical standards.
Gangnam JS Hospital is recognized for:
- Dedicated orthopedic focus
- Extensive experience in cartilage regeneration procedures
- Advanced imaging and surgical systems
- Structured post-operative rehabilitation programs
MSC Therapy vs Knee Replacement
Stem Cell TherapyTotal Knee ReplacementPreserves natural jointArtificial implantBiological regenerationMechanical solutionSuitable for selected patientsOften for advanced OALonger regeneration phaseFaster structural stability
Treatment choice depends on disease stage and patient goals.
Frequently Asked Questions
Is the stem cell therapy safe?
Umbilical cord blood–derived MSC therapy has undergone clinical evaluation in Korea and is approved for cartilage regeneration use. Individual medical assessment is required.
Is this the same as PRP?
No. PRP uses the patient’s own blood platelets. Umbilical cord MSC therapy uses cultured mesenchymal stem cells derived from donor cord blood.
Can it completely cure osteoarthritis?
The goal is cartilage regeneration and symptom improvement. Results vary based on joint condition.
International Patient Support
Gangnam JS Hospital provides structured evaluation and treatment planning for international patients seeking advanced regenerative knee therapy in Korea.
